ASCO Name Tag Logo Black S

PRESS RELEASE: Tactical Therapeutics, Inc. and Investigators to Present CTO Results at the Annual American Society of Clinical Oncology Meeting

NEW YORK–(BUSINESS WIRE)–Tactical Therapeutics, Inc., a clinical stage oncology drug development company, announced today it is scheduled to present study results of its lead drug Carboxyamidotriazole Orotate (CTO) at the annual American Society of Clinical Oncology meeting taking place May 29th to June 2nd in Chicago, Illinois. The poster will be presented by the investigators on Monday June 1st, 2015 at 1:15-4:45 PM in the Neuro-Oncology poster session, South Hall A, Poster Board 51, Abstract 2062, and describes results of Phase I studies CTO with Temodar® and radiation therapy in newly diagnosed glioblastoma. Read the full press release here: Tactical Therapeutics, Inc. and Investigators to Present CTO Results at the Annual American Society of Clinical Oncology Meeting

Share